GLP-1 News & Analysis
9 articles
Market Mood
Medicare Access to GLP-1s for Weight Loss Starting July 1
Starting July 1, Medicare beneficiaries who qualify will have access to GLP-1 weight-loss drugs for a cost of $50 per month. This initiative marks a significant change in the coverage of weight management treatments for older Americans. The availability of these drugs could potentially influence the healthcare market by increasing demand for GLP-1 medications. It is important for beneficiaries to be aware of possible side effects associated with these treatments.
Read More: Medicare Access to GLP-1s for Weight Loss Starting July 1
Novo Nordisk (NVO) Stock Target Set at $47 by Goldman Sachs
Goldman Sachs has maintained its Neutral rating and $47 price target on Novo Nordisk (NVO) after meeting with the management at the 47th Annual Global Healthcare Conference on June 9. This target represents a 7% upside from the closing price of 287.25 Danish kroner on June 12, which was up 1.66% for the day. Earlier this year, Novo shares dropped to a 52-week low near $37 following disappointing trial results for its drug CagriSema. Additionally, it held a 39% market share in the U.S. obesity and diabetes GLP-1 market, compared to Eli Lilly’s 60%.
Read More: Novo Nordisk (NVO) Stock Target Set at $47 by Goldman Sachs
High-Protein Whey Shortage Drives Prices Up Amid GLP-1 Demand
The demand for high-protein whey has surged due to increased interest in wellness products and the GLP-1 medication boom. This spike has created a substantial shortage in supply, affecting nutrition companies across the market. As a result, prices are reportedly rising significantly, impacting profit margins for companies that produce whey-based products. The ongoing trend towards health and wellness further emphasizes the importance of monitoring the whey market for potential investments.
Read More: High-Protein Whey Shortage Drives Prices Up Amid GLP-1 Demand
Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Wegovy continues to lead the GLP-1 market among weight-loss medications, despite competition from Eli Lilly's Foundayo. Specific market share percentages or sales figures were not provided. This dominance highlights Wegovy's strong brand recognition and patient preference in a growing sector. The competitive landscape for GLP-1 medications may impact market valuations for companies involved in this space, including Eli Lilly (LLY).
Read More: Wegovy Maintains Market Dominance Despite Eli Lilly GLP-1 Launch
Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Pfizer (PFE) has reported positive results from its GLP-1 drug PF-08653944, which shows weight loss of 10% to 12% by week 28 in Phase 2b trials. This drug features a monthly injection regimen, compared to the weekly doses of competitors like Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which may increase patient adherence. The weight loss drug market is projected to grow at nearly 25% annually through 2035, indicating strong competitive potential for Pfizer. As alternatives emerge, the dynamics of the anti-obesity drug market may be shifting, impacting shares of incumbents like NVO and LLY.
Read More: Pfizer (PFE) GLP-1 Drug Shows 10%-12% Weight Loss in Trials
Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
Eli Lilly (LLY) has reported significant financial benefits from its GLP-1 drug line, although specific figures are not detailed. Honeywell (HON) has made the strategic decision to divest a lower-margin unit, aiming to enhance overall profitability. This move could impact both companies' profit margins as LLY capitalizes on a high-demand market while HON restructures its operations. The market may see a shift as investors evaluate the potential growth of LLY and the implications of HON's divestiture.
Read More: Eli Lilly (LLY) sees GLP-1 windfall, Honeywell (HON) divests unit
GLP-1 Users Driving Retail Clothing Demand as Weight Loss Grows
Over 600,000 prescriptions for Novo Nordisk's Wegovy (NVO) were written by February 2023, indicating increased demand for weight loss drugs. Currently, nearly 13% of U.S. adults are on a GLP-1 medication, with adoption rates increasing from 11% in November 2024 to 16% in November 2025. Retailers are reporting a rise in customers seeking new clothing due to weight loss, with specific interest noted by services like Stitch Fix. Analysts predict that as accessibility improves, consumer spending on apparel is expected to grow significantly, particularly for smaller sizes.
Read More: GLP-1 Users Driving Retail Clothing Demand as Weight Loss Grows
GoodRx (GDRX) Offers Foundayo GLP-1 Medication for $149 Monthly
GoodRx (GDRX) has announced that it will offer the Foundayo GLP-1 medication starting at a price of $149 per month. This move provides a lower-cost option for patients seeking weight management treatments. The availability of this medication may impact the market for weight-loss pharmaceuticals by introducing competition. As healthcare costs continue to be a focus for consumers and providers, this pricing could influence purchasing decisions in the sector.
Read More: GoodRx (GDRX) Offers Foundayo GLP-1 Medication for $149 Monthly
Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions
Novo Nordisk's (NVO) Wegovy pill, launched in early January, has seen over 600,000 prescriptions written within three months, including more than 3,000 in its first week. This surge reflects a growing demand for GLP-1 treatments as patients previously deterred by injection methods now gravitate towards the oral option. The pill is priced between $149 to $299 per month, which analysts attribute to its early success. Despite this positive start, Novo's stock price remains under pressure as competition from Eli Lilly's newly approved GLP-1 product, Foundayo, arises.
Read More: Novo Nordisk (NVO) Wegovy Pill Launch Hits 600K Prescriptions